In Men With Obesity, T2DM Is Associated With Poor Trabecular Microarchitecture and Bone Strength and Low Bone Turnover.
Absorptiometry, Photon
Adult
Aged
Bone Density
/ physiology
Bone Remodeling
/ physiology
Bone and Bones
/ diagnostic imaging
Diabetes Mellitus, Type 2
/ complications
Flexural Strength
/ physiology
Follow-Up Studies
Humans
Hypogonadism
/ complications
Male
Middle Aged
Obesity
/ complications
Osteoporosis
/ diagnosis
Risk Factors
United States
/ epidemiology
Veterans
/ statistics & numerical data
Weight Reduction Programs
Weight-Bearing
/ physiology
bone microarchitecture
diabetes mellitus
obesity
osteoporosis
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
23 04 2021
23 04 2021
Historique:
received:
19
06
2020
pubmed:
5
2
2021
medline:
28
9
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
Obesity and type 2 Diabetes (T2D) are both associated with greater bone mineral density (BMD) but increased risk of fractures. The effect of the combination of both conditions on bone metabolism, microarchitecture, and strength in the obese population remains unknown. Data from 112 obese men were collected. Bone turnover and biochemical markers were measured by enzyme-linked immunosorbent assay, body composition and BMD at all sites were assessed by dual energy X-ray absorptiometry, whereas bone microarchitecture and strength (stiffness and failure load) were measured by high-resolution peripheral computed tomography. Data were compared among metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO) with and without T2D and between obese without and with T2D. Compared to MHO and MUHO without T2D, MUHO with T2D had significantly lower levels of osteocalcin ((7.49 ± 3.0 and 6.03 ± 2.47 vs 4.24 ± 2.72 ng/mL, respectively, P = 0.003) and C-terminal telopeptide of type I collagen (CTx) (0.28 ± 0.10 and 0.29 ± 0.13 vs 0.21 ± 0.15 ng/mL, respectively, P = 0.02). Dividing our subjects simply into those with and without T2D showed that obese men with T2D had significantly lower levels of osteocalcin (P = 0.003) and CTx (P = 0.005), greater trabecular separation at the tibia and radius (P = 0.03 and P = 0.04, respectively), and lower tibial failure load and stiffness (both P = 0.04), relative to obese men without T2D. In men, the combination of obesity and T2D is associated with reduced bone turnover and poorer trabecular bone microarchitecture and bone strength compared to those who are obese but without T2D, suggesting worse bone disease.
Identifiants
pubmed: 33537757
pii: 6127536
doi: 10.1210/clinem/dgab061
pmc: PMC8063237
doi:
Banques de données
ClinicalTrials.gov
['NCT03490513']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1362-1376Subventions
Organisme : NICHD NIH HHS
ID : R01 HD093047
Pays : United States
Informations de copyright
Published by Oxford University Press on behalf of the Endocrine Society 2021.
Références
BMC Endocr Disord. 2014 Feb 01;14:9
pubmed: 24484869
JAMA. 2011 Jun 1;305(21):2184-92
pubmed: 21632482
J Bone Miner Metab. 2009;27(4):479-84
pubmed: 19277453
Osteoporos Int. 2018 Mar;29(3):733-739
pubmed: 29290026
J Clin Invest. 2000 Dec;106(12):1553-60
pubmed: 11120762
Sports Med. 2014 Jan;44(1):37-53
pubmed: 24092631
J Obes. 2013;2013:409679
pubmed: 23533722
Eur J Endocrinol. 2015 Aug;173(2):167-74
pubmed: 26142101
Calcif Tissue Int. 2007 Apr;80(4):227-32
pubmed: 17406768
Int J Clin Pract. 2007 May;61(5):737-47
pubmed: 17493087
Biochem Biophys Res Commun. 2005 Jun 3;331(2):520-6
pubmed: 15850790
Front Endocrinol (Lausanne). 2020 May 15;11:277
pubmed: 32499757
Osteoporos Int. 2019 Oct;30(10):2079-2085
pubmed: 31214749
J Clin Endocrinol Metab. 1979 Apr;48(4):633-8
pubmed: 429508
J Bone Miner Res. 2000 Jan;15(1):13-9
pubmed: 10646109
N Engl J Med. 2017 May 18;376(20):1943-1955
pubmed: 28514618
Oncotarget. 2018 Jan 5;9(58):31302-31310
pubmed: 30131856
Diabetologia. 2014 Oct;57(10):2057-65
pubmed: 24908567
Obes Facts. 2017;10(3):207-215
pubmed: 28564650
Calcif Tissue Int. 2017 Dec;101(6):602-611
pubmed: 28856390
J Endocrinol. 2016 Sep;230(3):R115-30
pubmed: 27352896
J Bone Miner Res. 2011 May;26(5):965-73
pubmed: 21541999
J Clin Endocrinol Metab. 2014 Jun;99(6):2155-63
pubmed: 24606073
Osteoporos Int. 2005 Dec;16(12):1713-20
pubmed: 15940395
J Bone Miner Res. 2014 Jan;29(1):223-33
pubmed: 23775829
Nat Rev Endocrinol. 2017 Apr;13(4):208-219
pubmed: 27658727
Diabetes Metab Syndr Obes. 2014 Dec 04;7:587-91
pubmed: 25506234
J Bone Miner Res. 2000 Apr;15(4):613-20
pubmed: 10780852
PLoS One. 2017 Jul 19;12(7):e0181587
pubmed: 28723934
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3258-63
pubmed: 14978271
Cell Tissue Res. 2014 Oct;358(1):249-56
pubmed: 24859221
PLoS One. 2013 Apr 12;8(4):e55077
pubmed: 23593112
Clin Cases Miner Bone Metab. 2014 Jan;11(1):9-14
pubmed: 25002873
Int J Mol Sci. 2019 May 13;20(9):
pubmed: 31085992
Clin Cornerstone. 2007;8(3):29-37
pubmed: 18452840
J Clin Densitom. 2018 Apr - Jun;21(2):295-302
pubmed: 28256308
Osteoporos Int. 2005 Nov;16(11):1330-8
pubmed: 15928804
Bone. 2016 Jan;82:28-34
pubmed: 26211989
Arch Osteoporos. 2017 Oct 29;12(1):95
pubmed: 29082431
J Clin Endocrinol Metab. 2014 Sep;99(9):3290-7
pubmed: 24878039
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Int J Obes (Lond). 2014 Mar;38(3):423-31
pubmed: 23823329
Eat Weight Disord. 2018 Jun;23(3):293-302
pubmed: 29637521
Bone. 2002 Jun;30(6):842-8
pubmed: 12052451
Calcif Tissue Int. 2019 Nov;105(5):466-475
pubmed: 31511960
Obes Rev. 2015 Jul;16(7):581-606
pubmed: 25982085
Nutrients. 2019 Sep 06;11(9):
pubmed: 31489911
Bone. 2017 Jun;99:14-19
pubmed: 28323146
J Bone Miner Res. 2018 Jan;33(1):54-62
pubmed: 28929525
Arch Intern Med. 2008 Oct 27;168(19):2146-53
pubmed: 18955645